Publication | Open Access

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Acute Lung InjuryRespiratory Distress Syndrome (Pulmonary Critical Care)Randomised Phase 2AAcute CareHematologySafety TrialRespiratory Distress Syndrome (Neonatal Medicine)Start StudyAcute MedicineMedicineMesenchymal Stem CellEmergency Medicine